DBV Technologies Reports $98M Net Loss and Increased Operating Expenses for First Half of 2026

DBV Technologies S.A. reported a net loss of $98.0 million for the six months ended June 30, 2026, compared to a loss of $69.0 million for the same period in 2025. The company's operating income decreased to $1.6 million from $2.2 million year-over-year, primarily due to a reduction in research tax credits, which fell from $2.2 million to $1.6 million. Total operating expenses surged to $100.1 million, a 43% increase from $69.9 million in the prior year, driven by higher research and development costs, which rose by 17% to $64.6 million, and a significant increase in sales and marketing expenses, which jumped to $10.4 million from $0.7 million.

In terms of financial position, DBV Technologies had cash and cash equivalents of $174.9 million as of June 30, 2026, down from $194.2 million at the end of 2025. The company utilized $101.7 million in net cash for operating activities during the first half of 2026, compared to $53.6 million in the same period of 2025. The increase in cash outflows is attributed to ongoing investments in clinical development, manufacturing readiness, and preparations for the potential launch of the Viaskin Peanut patch, pending regulatory approval.

Strategically, DBV Technologies has made significant advancements in its manufacturing and commercialization efforts. The company entered into a Manufacturing Supply Agreement with Fareva La Vallée for the exclusive supply of peanut source material for the Viaskin Peanut patch, effective for eight years. Additionally, DBV signed letters of intent with Fareva Amboise and Integrated Commercialization Solutions for commercial-scale manufacturing and distribution services, respectively, as part of its preparations for a potential product launch in the United States.

Operationally, the company has expanded its workforce, averaging 170 employees in the first half of 2026, up from 109 in the same period of 2025. This increase reflects the company's transition from a clinical-stage organization to one focused on regulatory execution and commercial readiness. DBV Technologies is also preparing for a Biologics License Application (BLA) submission for the Viaskin Peanut patch, which is anticipated in the third quarter of 2026, following feedback from the FDA.

Looking ahead, DBV Technologies expects to maintain sufficient funding to support its operations through at least the third quarter of 2027, based on current forecasts. However, the company acknowledges that future cash requirements may vary significantly due to factors such as regulatory interactions, clinical enrollment pace, and foreign exchange fluctuations. The company may seek additional capital to support its long-term strategy, particularly as it advances toward potential commercialization of its product candidates.